All figures are in Canadian dollars.
This increase in sales and administration expenses is mainly due to Axcan's share of the marketing expenses generated by the launch of Urso in the U.S. marketplace. The main event of this exercise was the approval of Urso by the FDA . Axcan more than doubled its sales, due to strategic acquisitions of complementary products at the end of the previous exercise. Axcan sales are well divided among various important products such as Viokase , Urso , Modulon and Salofalk . Warnex Pharma Inc. This sale allowed the Company to refocus its operations on gastroenterology.